PPV23
ApprovedBiologic
CanSino Biologics Inc.PPV23 is one of 46 biologic programs targeting Memory. It is currently in Approved.
2
Indications
9
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
169 competitors in Memory
#DrugCompanyPhaseTrials
1Lexapro
AbbViePhase 3
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
Vivarin
HHikma Pharmaceuticals LLC
Phase 3
Pneumococcal Vaccine
GSKPhase 3
Bupropion XL
GSKPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 2
PPV23
CanSino Biologics Inc.Approved
Prograf
VVeloxis Pharmaceuticals
Phase 2
Solanezumab
Eli LillyPhase 3
Insulin Therapy
SanofiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Clinical Trial3 trials
PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
Completed·JJiangsu Province Centers for Disease Control and Prevention·Phase 1·NCT07025876·240 enrolled
Memory2 trials
Immunological Memory Induced by the 13valent Pneumococcal Conjugate(PCV13) and 23valent Plain Polysaccharide Vaccine(PPV23) in HIV-infected Patients
Unknown status·—·Phase 4·NCT03041051·40 enrolled
ANCA-Associated Vasculitis1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PPV23. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Approved[1]
- Company